Immunitas Therapeutics (United States)

Recent papers from Immunitas Therapeutics (United States)

1. First-in-human to proof-of-concept: why experimental medicine studies remain essential in human physiology and drug developmentPflügers Archiv - European Journal of Physiology · 2026
2. Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentanJournal of Comparative Effectiveness Research · 2025
3. Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentanJournal of Comparative Effectiveness Research · 2025
4. Abstract 1375: Abundance of KLRB1+ (CD161) T cells in anti-PD1 non responders coupled with enhanced tumor cytotoxicity of anti-CD161 (IMT-009) with anti-PD1 makes it a rational target for combination with anti-PD-(L)1 immunotherapyCancer Research · 2024
5. Anti CD161 Antibody IMT-009 Is a Novel Immunotherapeutic Agent That Effectively Blocks the Inhibitory CLEC2D/CD161 Axis in CLEC2D+ B Cell Hematological Malignancies Reinvigorating T and NK Cell Function Leading to Anti-Tumor BenefitBlood · 2023
6. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MSMultiple Sclerosis Journal · 2021
7. Clonally expanded, GPR15-expressing pathogenic effector T H 2 cells are associated with eosinophilic esophagitisScience Immunology · 2021
8. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicityCancer Immunology Immunotherapy · 2020
9. Methionine Enkephalin (MENK) Inhibits tumor growth through regulating CD4+Foxp3+ Regulatory T cells (Tregs) in miceCancer Biology & Therapy · 2015